Posted by Michael Wonder on 27 Jul 2022
FDA grants import discretion of Bracco's iodinated contrast medium Iomeron (iomeprol) to address supply shortages
27 July 2022 - Bracco Diagnostics today announced that the U.S. FDA granted import discretion of Iomeron (iomeprol) into the U.S. to address the ongoing iodinated contrast media shortage.
Iomeron (iomeprol) is a non-ionic iodinated contrast medium for intravascular use in adults in various imaging procedures. Currently registered in over 50 countries in Europe and Asia, it is not approved for use in the United States.
